PRESTIGE-AF

PREVENTION OF STROKE IN INTRACEREBRAL HAEMORRHAGE SURVIVORS WITH ATRIAL FIBRILLATION

Predictive Modelling of Risk Substudy

Participant Information Sheet

Chief Investigator: Prof Roland Veltkamp

WE INVITE YOU TO TAKE PART IN A SUBSTUDY OF PRESTIGE-AF

- Before you decide whether to take part, it is important for you to understand why the research is being done and what it will involve.
- Please take time to read the following information carefully. Discuss it with friends and relatives if you wish.
- You are free to decide whether to take part in this substudy. If you choose not to take part, or you chose to withdraw at any time, this will not affect your participation in the PRESTIGE-AF Study and it will not result in any disadvantages for you.
- Ask us if there is anything that is not clear or if you would like more information.

BACKGROUND

The PRESTIGE-AF Study offers a unique opportunity to develop tools for the prediction of individual risk of subsequent ischaemic or haemorrhagic stroke in patients with atrial fibrillation (AF), who have had a previous intracerebral haemorrhage (ICH) or bleeding within their brain. We will explore risk prediction using biomarkers, genetic variants, information from clinical data and brain imaging.

Biomarkers are molecules that can be measured in blood, giving doctors some information about their patient's status. Some examples of biomarkers are cholesterol and blood sugar levels. In

addition, small variations in our genetic material (DNA, or desoxyribonucleic acid) are also related to specific diseases or a different response to therapeutic interventions.
In this substudy, we aim to search for blood biomarkers and genetic variants related to the risk of suffering a new ischaemic stroke, ICH, or related to the response to anticoagulant medications.
Within this substudy, we will also assess the additive value of the information from blood biomarkers and genetic variants for predicting future events in addition to clinical information as well as results from brain imaging routinely collected during your treatment at hospital.

WHAT IS INVOLVED?

The only additional procedure for this substudy is a single collection of a blood sample which can be taken at your PRESTIGE-AF Study visit at the same time as your main study blood test.

If you decide to participate in the substudy up to 5 tubes of blood will be collected (up to 34 ml) which is about 7 teaspoons of blood.

Blood based biomarkers change over time, therefore we would like to take your sample at the start of the study so that we have a true baseline measure. If for any reason you do not want to have the sample taken during screening or at the enrolment visit, we can also take it at your one month follow up visit.

There are some situations where we will only take blood for the genetics part of the substudy. For example, if the research site does not have correct storage for biomarker samples or if you having your sample taken after the one month visit, (because your biomarkers may have changed). If you take part in the genetic component only, 3 tubes of blood will be drawn (18 ml).

If for any reason you do not want a genetic sample taken, you can take part in the biomarkers part of the substudy only, this will be 4 tubes of blood (28ml).

WHAT WILL HAPPEN TO THE SAMPLES

Your samples will be labelled with your PRESTIGE-AF participant number with no identifiable information about you. Blood samples will be held securely at the hospital until they are transferred to the PRESTIGE-AF biobank at the Neurovascular Research Laboratory, Vall d'Hebron Institute of Research (VHIR), in Barcelona, Spain. All transportation of samples will be made securely and in accordance with UK and EU guidance.

Your samples will be analysed to identify biomarkers and genetic variants related to the risk of stroke or the response to anticoagulant medications. For the biomarker component, blood based biomarkers will be measure at VHIR. For the genetic component, your samples will be transferred to a DNA database (DNA Banco Nacional in Salamanca, Spain) where DNA extraction will be performed. Then, they will be shipped to a genomic platform (which may be outside of the UK and EU) where genotyping will take place. (*genotyping* is the process of determining the genetic make-up of an individual by examining the DNA code in certain locations using biological assays).

If you consent to taking part in future research, any remaining blood sample left, after the analysis is complete, will be kept in the Neurovascular Research Laboratory in Barcelona to be used in future studies that may include genetic analysis.

PREDICTIVE MODELLING ANALYSIS

We will analyse data collected in the main PRESTIGE-AF study to look for potential associations. This research will be undertaken by the Institute of Clinical Epidemiology and Biometry at the University of Wuerzburg, Germany. We will also assess the additional effect of

adding information from blood biomarkers, genetic variants and neuroimaging information to the routine clinical information for identifying the best models to forecast new ischaemic stroke or ICH in future ICH patients.

POTENTIAL BENEFITS OF THE SUBSTUDY

There are no potential benefits for you personally from your participation in this substudy. However, if we can identify new biomarkers and genetic variants as well as new clinical and brain imaging information related to the response to oral anticoagulants, these results will be useful in the future to reduce the risk of suffering an ischaemic stroke or an ICH in patients with atrial fibrillation (AF), as well as to prevent side effects related with anticoagulants.

If you decide to participate in the substudy, the analysis of biomarkers from biological samples might reveal information relevant to your health. In accordance with current legislation, you have the right to be informed of the data obtained in the course of study. At the end of the study, we will send a report with the results of the biomarkers analysed to your recruiting centre. The recruiting centre will provide this information to you or your doctor. If you prefer not to be informed, your decision will be respected. However, when this information, according to the judgment of the responsible doctor, is necessary to prevent a serious injury to your health or that of your biological family, a close family member or a representative will be informed.

We will not give you any individual results from the genetic analyses that will be performed. We currently consider that outside of a clinical setting (in the context of genetic diagnosis) reporting of genetic results is of questionable value, and might even be harmful, for instance by causing undue alarm. We will however continuously monitor the situation regarding the way genetic results are presented, as scientific progress is made, and, if necessary, we will contact the local regulatory ethics committee for advice. Please note that if any change in strategy regarding reporting of genetic results was considered in the future, we would again seek your informed consent.

POTENTIAL RISK OF THE SUBSTUDY

There are no serious risks deriving from your participation in this substudy. Blood sampling can cause a burning sensation at the location where the needle is inserted into the skin and cause a small bruise. In very few cases a mild local infection that disappears within a few days can develop. More rarely, people may experience dizziness at the time of blood taking.

WHAT IF SOMETHING GOES WRONG?

Imperial College London holds insurance policies which apply to this study. If you experience harm or injury as a result of taking part in this study, you will be eligible to claim compensation without having to prove that Imperial College is at fault. This does not affect your legal rights to seek compensation.

If you are harmed due to someone's negligence, then you may have grounds for a legal action. Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have been treated during the course of this study then you should immediately inform the Investigator *(prestige-af@imperial.ac.uk).* The normal National Health Service mechanisms are also available to you. If you are still not satisfied with the response, you may contact the Imperial College, Research Governance and Integrity Team.

HOW WILL WE USE INFORMATION ABOUT YOU

Imperial College London is the sponsor for this study and will act as the data controller for this study. This means that we are responsible for looking after your information and using it properly. Imperial College London will keep you personal data for:

- 15 years after the study has finished in relation to data subject consent forms
- 15 years after the study has completed in relation to primary research data.

We will need to use information from you, your medical records, your GP or other healthcare providers for this research project.

This information will include:

- Your name
- Your contact details
- Your NHS Number
- Health information

People will use this information to do the research or to check your records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Some of your information will be sent to countries in the European Union. They must follow our rules about keeping your information safe.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

LEGAL BASIS

As a university we use personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study.

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the

interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research.

INTERNATIONAL TRANSFERS

There may be a requirement to transfer information to countries outside the European Economic Area (for example, to a research partner). Where this information contains your personal data, Imperial College London will ensure that it is transferred in accordance with data protection legislation. If the data is transferred to a country which is not subject to a European Commission (EC) adequacy decision in respect of its data protection standards, Imperial College London will enter into a data sharing agreement with the recipient organisation that incorporates EC approved standard contractual clauses that safeguard how your personal data is processed.

SHARING YOUR INFORMATION WITH OTHERS

For the purposes referred to in this privacy notice and relying on the bases for processing as set out above, we will share your personal data with certain third parties.

- Other College employees, agents, contractors and service providers (for example, suppliers of printing and mailing services, email communication services or web services, or suppliers who help us carry out any of the activities described above). Our third party service providers are required to enter into data processing agreements with us. We only permit them to process your personal data for specified purposes and in accordance with our policies.

- This clinical trial is part of a large European Union funded project. We are working with the following research collaborators across Europe who are all specialists in different fields. In order to answer the questions of our research we are all working together and therefore your data will be shared with:

- University Hospital Würzburg, Germany
- Julius-Maximilans Universitaet Würzburg, Germany
- Medizinische Universitaet Graz, Austria
- Kings College London, UK
- Fundacio Hospital Universitari Vall d'Hebron- Institut de Recerca, Spain
- Universite de Bordeaux, France
- Azienda Ospedaliera di Perugia, Italy
- Region Nordjylland (North Denmark Region) , Denmark
- Stroke Alliance for Europe, Belgium
- Heidelberg University Hospital, Germany
- University of Liverpool, UK

If you would like to find out more about the PRESTIGE-AF Project and what each partner does there is more information on our website www.prestige-af.org

WHAT ARE YOUR CHOICES ABOUT HOW YOUR INFORMATION IS USED

You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.

- We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you.

- If you agree to take part in this study, you will have the option to take part in future research using your data saved from this study.

WHERE CAN YOU FIND OUT MORE ABOUT HOW YOUR INFORMATION IS USED

You can find out more about how we use your information

- at www.hra.nhs.uk/information-about-patients/
- by asking one of the research team

- by sending an email to hello@prestige-af.org
- www.prestige-af.org/privacy-cookie-policy/

COMPLAINTS

If you wish to raise a complaint on how we have handled your personal data, please contact Imperial College London's Data Protection Officer via:

- email at dpo@imperial.ac.uk
- telephone on 020 7594 3502 and/or
- via post at Imperial College London, Data Protection Officer, Faculty Building Level 4, London SW7 2AZ.

If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner's Office (ICO). The ICO does recommend that you seek to resolve matters with the data controller (us) first before involving the regulator.

FUNDER

A group of international researchers formed the PRESTIGE AF consortium, which applied for research funding. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754517.

ETHICAL REVIEW

This research was designed and reviewed by a consortium of experts within the field. There are several monitoring boards in place that will continue to review the trial throughout, to ensure the safety of participants.

This research has been reviewed and approved by the London Surrey Borders Research Ethics Committee and the Medicines and Healthcare Products Regulatory Agency. The Health Research

Authority has approved this research to be conducted within the UK National Health Service.

FURTHER INFORMATION

It is important that you have enough information to decide whether to take part. If you have any questions, please contact the study team: *prestige-af@imperial.ac.uk*

Thank you for taking the time to read this information.

CONSENT FORM

Principal Investigator:

Participant ID:

	Please initial box
I confirm that I have read this information sheet and I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.	☐
I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.	☐
I understand that relevant sections of my medical notes and data collected during the study, may be looked at by responsible individuals from the NHS Trust or from regulatory authorities where it is relevant to my taking part in this research.	☐
I give permission for these individuals to access my records that are relevant to this research.	☐

I give / do not give (delete as applicable) consent for remaining blood samples and information collected about me to be used to support other research in the future, including those outside of the EEA. ☐

I understand that the information held and maintained by (*insert NHS Trust*) and other UK NHS bodies may be used to help contact me or provide information about my health status. ☐

I consent to take part the whole substudy / biomarkers component only/ genetics component only (*delete as appropriate)* ☐

Name of Participant	Date	Signature
Name of Investigator taking consent	Date	Signature
Name of Witness (If oral consent given)	Date	Signature

When completed: 1 for Participant, 1 for investigator site file, 1 to be kept in medical notes

.